However, the question of whether apoB/apoA-I should be introduced into guidelines as a target for therapy in people with dyslipidemia is a debated issue, as some reports indicated that apoB/apoA-I were better predictors of CVD risk compared with traditional lipid ratios [22,23], and other studies reported that apoB/apoA-I and non-HDL-C/HDL-C were comparable in terms of predicting CVD risk [8,24]. This evidence concerns the gene APOB and metabolic syndrome.